Cambrex Corp. (CBM) Misses Q1 EPS by 5c, Revenue Tops Consensus
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/17/2026
- Wall Street indexes slip as oil prices rise, retail results awaited
- Trump threatens to bomb Oman over Iran stance
- Why this Wall Street strategist says the "trade is long gold"
- U.S. EV market shows signs of bottoming out: Bernstein
- Micron rises as White House presses Apple to avoid Chinese memory chips
- Wall Street indexes slip as oil prices rise, retail results awaited
- Oil settles up over $2 as Iran war stalemate stokes supply concerns
- Trump threatens to bomb Oman over Iran stance
- BofA sees Micron EPS topping $230 by FY30, calls peak fears overblown
- L3Harris CEO steps down amid conduct review, shares drop
Cambrex Reports First Quarter 2018 Financial Results
May 3, 2018 6:45 AM EDT- Net Revenue increased 34% vs. prior year quarter, which includes a favorable impact from the adoption of ASC 606 -
- 2018 full year financial guidance reaffirmed -
- Conference call at 8:30 a.m. ET on May 3, 2018 -
EAST RUTHERFORD, N.J., May 03, 2018 (GLOBE NEWSWIRE) -- Cambrex Corporation (NYSE: CBM), a leading manufacturer of small molecule innovator and generic Active Pharmaceutical Ingredients (APIs), reports results for the first quarter ended March 31, 2018.
Highlights
... More